Webinar LipidBrick® IM21.7c Novel Cationic Lipid for LNP Formulation

Webinar LipidBrick^®IM21.7c Novel Cationic Lipid for LNP Formulation

LipidBrick^® IM21.7c Novel Cationic Lipid for LNP Formulation

LipidBrick® IM21.7c cationic lipids offer new possibilities in LNP engineering for RNA therapeutics and its Impact of a novel cationic lipid on both mRNA, LNP properties and in vivo biodistribution.

In this webinar Dr. Malik Hellal , Dr. Claire Guéguen and Dr. Julien Dépollier will present how Polyplus developed LipidBrick® IM21.7c to overcome current limitations of ionizable lipids by enabling a wider in vivo biodistribution and decreasing accumulation in the liver. LipidBrick® IM21.7c aims to to improve LNP formulation to meet the growing demand of the mRNA therapeutic market.

What You Will Learn:

Improves efficiency of LNPs
Improves biodistribution of LNPs to broaden their use
Ensures drug and patient safety with improved particle stability

Clear form data

Please Complete the Form

First Name *

Last Name *

E-Mail *

Phone Number *

Company *

Job Title *

Address *

Country *

Postal Code *

I would like to sign up for newsletters from Sartorius (Sartorius AG and its affiliated companies) based of my personal interests.
I can revoke my consent at any time with effect for the future by sending an e-mail to unsubscribe@sartorius.com or by clicking on the "unsubscribe" link in e-mails I have received.

* These fields are required Information on the use of your data can be found in our privacy policy

LipidBrick® IM21.7c Novel Cationic Lipid for LNP Formulation

Please Complete the Form

Complete Form to Watch the Webinar

LipidBrick^® IM21.7c Novel Cationic Lipid for LNP Formulation